跳至主要内容
临床试验/NCT00559546
NCT00559546已完成4 期

Montelukast as a Controller of Atopic Syndrome

University of Helsinki1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
61
试验地点
1
主要终点
Allergic symptoms

研究概览

简要总结

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Wheal diameter at least 4 mm in skin-prick test for both birch and timothy
  • Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following:
  • Allergic conjunctivitis
  • Atopic eczema
  • Oral symptoms from vegetables or fruits by cross reactivity to birch
  • Urticaria in allergen exposure

排除标准

  • Need for regular treatment with glucocorticoids
  • Current smoking
  • Other major disease or need for regular drug treatment
  • Pregnancy

研究组 & 干预措施

1

Active Comparator

3 weeks of Montelukast and 3 weeks of placebo treatment

干预措施: montelukast (Drug)

2

Active Comparator

3 weeks of placebo and 3 weeks of montelukast treatment

干预措施: montelukast (Drug)

结局指标

主要结局

Allergic symptoms

时间窗: 3 weeks

次要结局

  • Need for antihistamines or inhaled beta-2-agonists to relieve symptoms(3 weeks)
  • Exhaled nitric oxide concentration(3 weeks)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Montelukast as a Controller of Atopic Syndrome | 临床试验